Waldenstrom Macroglobulinemia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

20:04 EDT 2 Aug 2017 | BioPortfolio Reports

DelveInsight's, Waldenstrom Macroglobulinemia Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Waldenstrom Macroglobulinemia. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Waldenstrom Macroglobulinemia. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
AbbVie Inc
Amgen Inc.
Aurigene Discovery Technologies Limited
Bayer AG
BeiGene Ltd.
Calithera Biosciences Inc.
Celgene Corporation
Genentech Inc.
Gilead Sciences Inc.
Hutchison MediPharma Limited
IGF Oncology LLC.
Incyte Corporation
Juno Therapeutics Inc.
Karyopharm Therapeutics Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Novartis AG
Ono Pharmaceutical Co. Ltd.
Portola Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited 38
Vivolux AB
Waldenstrom Macroglobulinemia Pipeline Drugs
Waldenstrom Macroglobulinemia Pipeline Assessment
Waldenstrom Macroglobulinemia Pipeline Analysis
Waldenstrom Macroglobulinemia Drugs under Development
Waldenstrom Macroglobulinemia Discovery drugs
Waldenstrom Macroglobulinemia Preclinical drugs
Waldenstrom Macroglobulinemia Phase I drugs
Waldenstrom Macroglobulinemia Phase II drugs
Waldenstrom Macroglobulinemia Phase III Pipeline Drugs Assessment
Waldenstrom Macroglobulinemia Preregistration drugs
Waldenstrom Macroglobulinemia Molecules in pipeline

Original Article: Waldenstrom Macroglobulinemia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250


More From BioPortfolio on "Waldenstrom Macroglobulinemia Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...